Abstract
In 2004, approximately 9 million people worldwide experienced a stroke, with the majority being ischemic in nature. While the prognosis for recovery can be good, long-term survival and functional outcome can be improved. Stroke survivors are at an increased risk for recurrent stroke and other ischemic vascular events and face significant cross-risk for atherothrombotic conditions affecting the coronary and peripheral vascular beds. As such, the secondary prevention of ischemic events in patients with stroke has focused on the treatment of atherosclerosis as a whole, with antiplatelet therapy playing a key role. There is some controversy regarding optimal antiplatelet therapy following stroke. The appropriate use of specific agents, the impact of stroke type and proper dosing, and other questions stem from an incomplete understanding of the issues, variability in clinical trial data, diversity in patient demographics, and differences in antiplatelet regimens. This review evaluates the clinical evidence for antiplatelet therapy in patients that have suffered an ischemic stroke, with an emphasis on balancing the benefits of a particular antiplatelet regimen with its attendant risk profile. The critical assessment of emerging trial data and its impact on existing treatment guidelines may aid in choosing the most appropriate antiplatelet regimen for comprehensive secondary prevention following stroke.
Keywords: Antiplatelet therapy, aspirin, clopidogrel, dipyridamole, ischemic stroke, secondary prevention, transient ischemic attack, atherosclerosis, cerebrovascular disease, hyperlipidemia
Current Vascular Pharmacology
Title: Antiplatelet Therapy for Secondary Prevention in Stroke – Making the Right Choice
Volume: 10 Issue: 2
Author(s): Geoffrey Ling
Affiliation:
Keywords: Antiplatelet therapy, aspirin, clopidogrel, dipyridamole, ischemic stroke, secondary prevention, transient ischemic attack, atherosclerosis, cerebrovascular disease, hyperlipidemia
Abstract: In 2004, approximately 9 million people worldwide experienced a stroke, with the majority being ischemic in nature. While the prognosis for recovery can be good, long-term survival and functional outcome can be improved. Stroke survivors are at an increased risk for recurrent stroke and other ischemic vascular events and face significant cross-risk for atherothrombotic conditions affecting the coronary and peripheral vascular beds. As such, the secondary prevention of ischemic events in patients with stroke has focused on the treatment of atherosclerosis as a whole, with antiplatelet therapy playing a key role. There is some controversy regarding optimal antiplatelet therapy following stroke. The appropriate use of specific agents, the impact of stroke type and proper dosing, and other questions stem from an incomplete understanding of the issues, variability in clinical trial data, diversity in patient demographics, and differences in antiplatelet regimens. This review evaluates the clinical evidence for antiplatelet therapy in patients that have suffered an ischemic stroke, with an emphasis on balancing the benefits of a particular antiplatelet regimen with its attendant risk profile. The critical assessment of emerging trial data and its impact on existing treatment guidelines may aid in choosing the most appropriate antiplatelet regimen for comprehensive secondary prevention following stroke.
Export Options
About this article
Cite this article as:
Ling Geoffrey, Antiplatelet Therapy for Secondary Prevention in Stroke – Making the Right Choice, Current Vascular Pharmacology 2012; 10 (2) . https://dx.doi.org/10.2174/157016112799305058
DOI https://dx.doi.org/10.2174/157016112799305058 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Advancements in Arterial Stiffness: Novel Therapeutic Frontiers
Arterial stiffness, a hallmark of cardiovascular disease, poses significant challenges in contemporary healthcare. This thematic issue delves into the multifaceted landscape of arterial stiffness and explores cutting-edge therapeutic interventions aimed at mitigating its adverse effects. Within these pages, readers will find a comprehensive overview of the mechanisms underlying arterial stiffness, ...read more
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Vascular Calcification Revisited: A New Perspective for Phosphate Transport
Current Cardiology Reviews Targeting Cancer Stem Cells with Natural Products
Current Drug Targets Therapy of Hepatocellular Carcinoma with Rhenium-188 Lipiodol
Current Radiopharmaceuticals On-Pump Coronary Artery Bypass Graft: The State of the Art
Reviews on Recent Clinical Trials Phase I Clinical Trial of Exherin (ADH-1) in Patients with Advanced Solid Tumors
Current Clinical Pharmacology Surgical Ventricular Restoration: An Operation To Reverse Remodeling - The Basic Science (Part I)
Current Cardiology Reviews ACKNOWLEDGEMENTS TO THE REVIEWERS
Current Hypertension Reviews Effects of Different Etiologies of Anterior Circulation Tandem Lesions on Short-term Prognosis of Acute Ischemic Stroke
Current Neurovascular Research The Plasminogen Activation System Promotes Neurorepair in the Ischemic Brain
Current Drug Targets Levosimendan: From Basic Science to Clinical Trials
Recent Patents on Cardiovascular Drug Discovery Cholesterol and LDL Relate to Neuritic Plaques and to APOE4 Presence but Not to Neurofibrillary Tangles
Current Alzheimer Research Lung Ultrasound in the Management of Acute Decompensated Heart Failure
Current Cardiology Reviews Can Non-invasive Biomarkers Lead to an Earlier Diagnosis of Alzheimer’s Disease?
Current Alzheimer Research Health Benefits of Manuka Honey as an Essential Constituent for Tissue Regeneration
Current Drug Metabolism Gene Therapy for Dentin Regeneration with Bone Morphogenetic Proteins
Current Gene Therapy Association Between Adiposity Indices and Blood Pressure is Stronger in Sarcopenic Obese Women
Current Hypertension Reviews Fangchinoline Inhibited Proliferation of Neoplastic B-lymphoid Cells and Alleviated Sjögren’s Syndrome-like Responses in NOD/Ltj Mice via the Akt/mTOR Pathway
Current Molecular Pharmacology Impact of Drug Metabolism/Pharmacokinetics and their Relevance Upon Salviabased Drug Discovery
Current Drug Metabolism Polyphenols: Potential Use in the Prevention and Treatment of Cardiovascular Diseases
Current Pharmaceutical Design Galanin: A Novel Therapeutic Target for Depression, Anxiety Disorders and Drug Addiction?
CNS & Neurological Disorders - Drug Targets